Jones S, Kuhn J, Greco A, Thompson DS, Raefsky EL, Patton JF, Hainsworth JD, McKay CE, Greenwell SL, Baker NM, Burris HA.  A phase I study of oral topotecan in patients with refractory and/or advanced malignancies.  Am J Cancer 3: 137-324, 2004.

Cloughesy T, Kuhn J, Robins HI, Abrey L, Wen P, Fink K, Lieberman FS, Mehta M, Chang S, Yung A, DeAngelis L, Schiff D, Junck L, Groves M, Wright J, Lamborn K, Sebti S, Prados M.  A Phase I trial of R115777 in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs (EIAEDs).  J Clin Oncol 23:6647-6656, 2005.

Prados M, Lamborn K, Yung WKA, Jaeckle K, Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Change S, Nicolas KM, Schiff D, Greenberg H, Junck L, Fink K, Hess K, Kuhn J.  A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma:  A North American Brain Tumor Consortium Study.  Neuro-Oncology 8:189-193, 2006.

Grabinski JL, Smith LS, Chisholm GB, Drengler, Rodriguez GI, Lang AS, Kalter SP, Garner AM, Fichtel LM, Hillsten J, Pollock BH, Kuhn JG.  Genotypic and allelic frequencies of SULT1A1 polymorphism in women receiving adjuvant tamoxifen therapy.  Breast Cancer Res Treat 95:13-16, 2006.

Kuhn JG, Chang SM, Wen PY, Cloughesy TF, Greenberg H, Schiff
D, Conrad C, Fink KL, Robins HI, Mehta M, DeAngelis L, Raizer J,
Hess K, Lamborn KR, Dance J, Prados MD.  Pharmacokinetic and
Tumor distribution characteristics of temsirolimus in patients with
Recurrent malignant glioma.  Clin Cancer Res 13:7401-7406,2007.

More information about Dr. Kuhn
> Return to Dr. Kuhn's Home Page